Lymph  ||| S:0 E:6 ||| FW
node-positive  ||| S:6 E:20 ||| FW
stage  ||| S:20 E:26 ||| FW
IIIC  ||| S:26 E:31 ||| FW
ovarian  ||| S:31 E:39 ||| FW
cancer ||| S:39 E:45 ||| NN
:  ||| S:45 E:47 ||| :
a  ||| S:47 E:49 ||| DT
separate  ||| S:49 E:58 ||| JJ
entity ||| S:58 E:64 ||| NN
?  ||| S:64 E:66 ||| .
Ovarian  ||| S:66 E:74 ||| JJ
cancer  ||| S:74 E:81 ||| NN
spreads  ||| S:81 E:89 ||| NNS
via  ||| S:89 E:93 ||| IN
the  ||| S:93 E:97 ||| DT
retroperitoneal  ||| S:97 E:113 ||| JJ
lymphatics ||| S:113 E:123 ||| NN
,  ||| S:123 E:125 ||| ,
and  ||| S:125 E:129 ||| CC
these  ||| S:129 E:135 ||| DT
lymph  ||| S:135 E:141 ||| JJ
nodes  ||| S:141 E:147 ||| NNS
frequently  ||| S:147 E:158 ||| RB
contain  ||| S:158 E:166 ||| VB
metastasis ||| S:166 E:176 ||| NNS
.  ||| S:176 E:178 ||| .
A  ||| S:178 E:180 ||| DT
subset  ||| S:180 E:187 ||| NN
of  ||| S:187 E:190 ||| IN
patients  ||| S:190 E:199 ||| NNS
whose  ||| S:199 E:205 ||| WP$
disease  ||| S:205 E:213 ||| NN
was  ||| S:213 E:217 ||| VBD
classified  ||| S:217 E:228 ||| VBN
as  ||| S:228 E:231 ||| IN
stage  ||| S:231 E:237 ||| NN
IIIC  ||| S:237 E:242 ||| NNP
has  ||| S:242 E:246 ||| VBZ
retroperitoneal  ||| S:246 E:262 ||| JJ
lymph  ||| S:262 E:268 ||| JJ
node  ||| S:268 E:273 ||| JJ
metastases  ||| S:273 E:284 ||| NN
in  ||| S:284 E:287 ||| IN
the  ||| S:287 E:291 ||| DT
pelvic  ||| S:291 E:298 ||| JJ
and ||| S:298 E:301 ||| CC
/ ||| S:301 E:302 ||| NNP
or  ||| S:302 E:305 ||| CC
para-aortic  ||| S:305 E:317 ||| JJ
lymph  ||| S:317 E:323 ||| JJ
nodes  ||| S:323 E:329 ||| NN
without  ||| S:329 E:337 ||| IN
intraperitoneal  ||| S:337 E:353 ||| JJ
carcinomatosis  ||| S:353 E:368 ||| NN
and  ||| S:368 E:372 ||| CC
was  ||| S:372 E:376 ||| VBD
upstaged  ||| S:376 E:385 ||| VBN
from  ||| S:385 E:390 ||| IN
stage  ||| S:390 E:396 ||| NN
I  ||| S:396 E:398 ||| PRP
to  ||| S:398 E:401 ||| TO
IIIB  ||| S:401 E:406 ||| NNP
diseases  ||| S:406 E:415 ||| NNS
based  ||| S:415 E:421 ||| VBN
on  ||| S:421 E:424 ||| IN
these  ||| S:424 E:430 ||| DT
findings ||| S:430 E:438 ||| NNS
.  ||| S:438 E:440 ||| .
Patients  ||| S:440 E:449 ||| NNS
undergoing  ||| S:449 E:460 ||| VBG
cytoreductive  ||| S:460 E:474 ||| JJ
surgery  ||| S:474 E:482 ||| NN
for  ||| S:482 E:486 ||| IN
advanced-stage  ||| S:486 E:501 ||| FW
ovarian  ||| S:501 E:509 ||| FW
cancer  ||| S:509 E:516 ||| FW
undergo  ||| S:516 E:524 ||| FW
concomitant  ||| S:524 E:536 ||| FW
retroperitoneal  ||| S:536 E:552 ||| FW
lymphadenectomy  ||| S:552 E:568 ||| FW
in  ||| S:568 E:571 ||| IN
an  ||| S:571 E:574 ||| DT
effort  ||| S:574 E:581 ||| NN
to  ||| S:581 E:584 ||| TO
improve  ||| S:584 E:592 ||| VB
their  ||| S:592 E:598 ||| PRP$
survival ||| S:598 E:606 ||| NN
.  ||| S:606 E:608 ||| .
Stratification  ||| S:608 E:623 ||| NNP
of  ||| S:623 E:626 ||| IN
patients  ||| S:626 E:635 ||| NNS
with  ||| S:635 E:640 ||| IN
stage  ||| S:640 E:646 ||| NN
IIIC  ||| S:646 E:651 ||| NNP
ovarian  ||| S:651 E:659 ||| JJ
cancer  ||| S:659 E:666 ||| NN
by  ||| S:666 E:669 ||| IN
lymph  ||| S:669 E:675 ||| JJ
node  ||| S:675 E:680 ||| JJ
status  ||| S:680 E:687 ||| NN
and  ||| S:687 E:691 ||| CC
presence  ||| S:691 E:700 ||| NN
and  ||| S:700 E:704 ||| CC
extent  ||| S:704 E:711 ||| NN
of  ||| S:711 E:714 ||| IN
metastatic  ||| S:714 E:725 ||| JJ
disease  ||| S:725 E:733 ||| NN
in  ||| S:733 E:736 ||| IN
the  ||| S:736 E:740 ||| DT
peritoneal  ||| S:740 E:751 ||| JJ
cavity  ||| S:751 E:758 ||| NN
has  ||| S:758 E:762 ||| VBZ
been  ||| S:762 E:767 ||| VBN
performed ||| S:767 E:776 ||| VBN
.  ||| S:776 E:778 ||| .
Studies  ||| S:778 E:786 ||| NNS
have  ||| S:786 E:791 ||| VBP
determined  ||| S:791 E:802 ||| VBN
the  ||| S:802 E:806 ||| DT
impact  ||| S:806 E:813 ||| NN
on  ||| S:813 E:816 ||| IN
disease-free  ||| S:816 E:829 ||| JJ
and  ||| S:829 E:833 ||| CC
overall  ||| S:833 E:841 ||| JJ
survivals  ||| S:841 E:851 ||| NN
of  ||| S:851 E:854 ||| IN
the  ||| S:854 E:858 ||| DT
resection  ||| S:858 E:868 ||| NN
of  ||| S:868 E:871 ||| IN
retroperitoneal  ||| S:871 E:887 ||| JJ
lymph  ||| S:887 E:893 ||| JJ
nodes  ||| S:893 E:899 ||| NN
as  ||| S:899 E:902 ||| IN
part  ||| S:902 E:907 ||| NN
of  ||| S:907 E:910 ||| IN
primary  ||| S:910 E:918 ||| JJ
and  ||| S:918 E:922 ||| CC
secondary  ||| S:922 E:932 ||| JJ
cytoreductive  ||| S:932 E:946 ||| JJ
operations ||| S:946 E:956 ||| NNS
.  ||| S:956 E:958 ||| .
The  ||| S:958 E:962 ||| DT
overall  ||| S:962 E:970 ||| JJ
survival  ||| S:970 E:979 ||| NN
of  ||| S:979 E:982 ||| IN
patients  ||| S:982 E:991 ||| NNS
with  ||| S:991 E:996 ||| IN
stage  ||| S:996 E:1002 ||| NN
IIIC  ||| S:1002 E:1007 ||| NNP
ovarian  ||| S:1007 E:1015 ||| JJ
cancer  ||| S:1015 E:1022 ||| NN
based  ||| S:1022 E:1028 ||| VBN
on  ||| S:1028 E:1031 ||| IN
retroperitoneal  ||| S:1031 E:1047 ||| FW
lymph  ||| S:1047 E:1053 ||| FW
node  ||| S:1053 E:1058 ||| FW
metastasis  ||| S:1058 E:1069 ||| FW
without  ||| S:1069 E:1077 ||| FW
peritoneal  ||| S:1077 E:1088 ||| FW
carcinomatosis  ||| S:1088 E:1103 ||| FW
is  ||| S:1103 E:1106 ||| VBZ
58 ||| S:1106 E:1108 ||| CD
%  ||| S:1108 E:1110 ||| NN
to  ||| S:1110 E:1113 ||| TO
84 ||| S:1113 E:1115 ||| CD
%  ||| S:1115 E:1117 ||| NN
compared  ||| S:1117 E:1126 ||| VBN
with  ||| S:1126 E:1131 ||| IN
18 ||| S:1131 E:1133 ||| CD
%  ||| S:1133 E:1135 ||| NN
to  ||| S:1135 E:1138 ||| TO
36 ||| S:1138 E:1140 ||| CD
%  ||| S:1140 E:1142 ||| NN
for  ||| S:1142 E:1146 ||| IN
those  ||| S:1146 E:1152 ||| DT
with  ||| S:1152 E:1157 ||| IN
macroscopic  ||| S:1157 E:1169 ||| JJ
peritoneal  ||| S:1169 E:1180 ||| JJ
carcinomatosis ||| S:1180 E:1194 ||| NN
.  ||| S:1194 E:1196 ||| .
Although  ||| S:1196 E:1205 ||| IN
the  ||| S:1205 E:1209 ||| DT
performance  ||| S:1209 E:1221 ||| NN
of  ||| S:1221 E:1224 ||| IN
a  ||| S:1224 E:1226 ||| DT
pelvic  ||| S:1226 E:1233 ||| JJ
and  ||| S:1233 E:1237 ||| CC
para-aortic  ||| S:1237 E:1249 ||| JJ
lymphadenectomy  ||| S:1249 E:1265 ||| NN
in  ||| S:1265 E:1268 ||| IN
patients  ||| S:1268 E:1277 ||| NNS
with  ||| S:1277 E:1282 ||| IN
stage  ||| S:1282 E:1288 ||| NN
IIIC  ||| S:1288 E:1293 ||| NN
to  ||| S:1293 E:1296 ||| TO
IV  ||| S:1296 E:1299 ||| NNP
diseases  ||| S:1299 E:1308 ||| NNS
has  ||| S:1308 E:1312 ||| VBZ
been  ||| S:1312 E:1317 ||| VBN
reported  ||| S:1317 E:1326 ||| VBN
to  ||| S:1326 E:1329 ||| TO
prolong  ||| S:1329 E:1337 ||| VB
survival ||| S:1337 E:1345 ||| NN
,  ||| S:1345 E:1347 ||| ,
an  ||| S:1347 E:1350 ||| DT
international  ||| S:1350 E:1364 ||| JJ
randomized  ||| S:1364 E:1375 ||| JJ
study  ||| S:1375 E:1381 ||| NN
did  ||| S:1381 E:1385 ||| VBD
not  ||| S:1385 E:1389 ||| RB
confirm  ||| S:1389 E:1397 ||| VB
this  ||| S:1397 E:1402 ||| DT
finding ||| S:1402 E:1409 ||| NN
.  ||| S:1409 E:1411 ||| .
Patients  ||| S:1411 E:1420 ||| NNS
who  ||| S:1420 E:1424 ||| WP
undergo  ||| S:1424 E:1432 ||| VBP
secondary  ||| S:1432 E:1442 ||| JJ
resection  ||| S:1442 E:1452 ||| NN
of  ||| S:1452 E:1455 ||| IN
isolated  ||| S:1455 E:1464 ||| FW
recurrent  ||| S:1464 E:1474 ||| FW
lymph  ||| S:1474 E:1480 ||| FW
node  ||| S:1480 E:1485 ||| FW
metastasis  ||| S:1485 E:1496 ||| FW
have  ||| S:1496 E:1501 ||| VBP
a  ||| S:1501 E:1503 ||| DT
better  ||| S:1503 E:1510 ||| JJR
survival  ||| S:1510 E:1519 ||| NN
than  ||| S:1519 E:1524 ||| IN
those  ||| S:1524 E:1530 ||| DT
with  ||| S:1530 E:1535 ||| IN
more  ||| S:1535 E:1540 ||| RBR
extensive  ||| S:1540 E:1550 ||| JJ
recurrent  ||| S:1550 E:1560 ||| JJ
disease ||| S:1560 E:1567 ||| NN
.  ||| S:1567 E:1569 ||| .
These  ||| S:1569 E:1575 ||| DT
data  ||| S:1575 E:1580 ||| NNS
support  ||| S:1580 E:1588 ||| VBP
the  ||| S:1588 E:1592 ||| DT
stratification  ||| S:1592 E:1607 ||| NN
of  ||| S:1607 E:1610 ||| IN
patients  ||| S:1610 E:1619 ||| NNS
with  ||| S:1619 E:1624 ||| IN
stage  ||| S:1624 E:1630 ||| NN
IIIC  ||| S:1630 E:1635 ||| NNP
ovarian  ||| S:1635 E:1643 ||| JJ
cancer  ||| S:1643 E:1650 ||| NN
based  ||| S:1650 E:1656 ||| VBN
on  ||| S:1656 E:1659 ||| IN
the  ||| S:1659 E:1663 ||| DT
finding  ||| S:1663 E:1671 ||| NN
of  ||| S:1671 E:1674 ||| IN
metastasis  ||| S:1674 E:1685 ||| VBG
to  ||| S:1685 E:1688 ||| TO
the  ||| S:1688 E:1692 ||| DT
retroperitoneal  ||| S:1692 E:1708 ||| JJ
lymph  ||| S:1708 E:1714 ||| JJ
nodes  ||| S:1714 E:1720 ||| NN
without  ||| S:1720 E:1728 ||| IN
peritoneal  ||| S:1728 E:1739 ||| JJ
carcinomatosis  ||| S:1739 E:1754 ||| NN
versus  ||| S:1754 E:1761 ||| IN
those  ||| S:1761 E:1767 ||| DT
who  ||| S:1767 E:1771 ||| WP
have  ||| S:1771 E:1776 ||| VBP
peritoneal  ||| S:1776 E:1787 ||| JJ
carcinomatosis ||| S:1787 E:1801 ||| NN
.  ||| S:1801 E:1803 ||| .
The  ||| S:1803 E:1807 ||| DT
International  ||| S:1807 E:1821 ||| NNP
Federation  ||| S:1821 E:1832 ||| NNP
of  ||| S:1832 E:1835 ||| IN
Gynecology  ||| S:1835 E:1846 ||| NNP
and  ||| S:1846 E:1850 ||| CC
Obstetrics  ||| S:1850 E:1861 ||| NNP
Committee  ||| S:1861 E:1871 ||| NNP
should  ||| S:1871 E:1878 ||| MD
consider  ||| S:1878 E:1887 ||| VB
modifying  ||| S:1887 E:1897 ||| VBN
the  ||| S:1897 E:1901 ||| DT
ovarian  ||| S:1901 E:1909 ||| JJ
cancer  ||| S:1909 E:1916 ||| NN
staging  ||| S:1916 E:1924 ||| NN
system  ||| S:1924 E:1931 ||| NN
by  ||| S:1931 E:1934 ||| IN
further  ||| S:1934 E:1942 ||| JJ
stratifying  ||| S:1942 E:1954 ||| JJ
stage  ||| S:1954 E:1960 ||| NN
III  ||| S:1960 E:1964 ||| NNP
disease ||| S:1964 E:1971 ||| NN
.  ||| S:1971 E:1973 ||| .
Although  ||| S:1973 E:1982 ||| IN
systematic  ||| S:1982 E:1993 ||| JJ
lymphadenectomy  ||| S:1993 E:2009 ||| NN
during  ||| S:2009 E:2016 ||| IN
primary  ||| S:2016 E:2024 ||| JJ
cytoreductive  ||| S:2024 E:2038 ||| JJ
surgery  ||| S:2038 E:2046 ||| NN
does  ||| S:2046 E:2051 ||| VBZ
not  ||| S:2051 E:2055 ||| RB
appear  ||| S:2055 E:2062 ||| VB
to  ||| S:2062 E:2065 ||| TO
improve  ||| S:2065 E:2073 ||| VB
overall  ||| S:2073 E:2081 ||| JJ
survival ||| S:2081 E:2089 ||| NN
,  ||| S:2089 E:2091 ||| ,
resection  ||| S:2091 E:2101 ||| VBG
of  ||| S:2101 E:2104 ||| IN
isolated  ||| S:2104 E:2113 ||| FW
lymph  ||| S:2113 E:2119 ||| FW
node  ||| S:2119 E:2124 ||| FW
metastasis  ||| S:2124 E:2135 ||| FW
and  ||| S:2135 E:2139 ||| CC
recurrences  ||| S:2139 E:2151 ||| NN
in  ||| S:2151 E:2154 ||| IN
lymph  ||| S:2154 E:2160 ||| JJ
nodes  ||| S:2160 E:2166 ||| NN
may  ||| S:2166 E:2170 ||| MD
be  ||| S:2170 E:2173 ||| VB
associated  ||| S:2173 E:2184 ||| VBN
with  ||| S:2184 E:2189 ||| IN
a  ||| S:2189 E:2191 ||| DT
survival  ||| S:2191 E:2200 ||| NN
benefit ||| S:2200 E:2207 ||| NN
.  ||| S:2207 E:2209 ||| .
